Analysis of outcome in patients with different primary localisation of neuroendocrine tumors after PRRT. 10 years single institution experience.

OBJECTIVE: The aim of this retrospective study is to analyze the outcome and survival of patients with well-differentiated metastatic neuroendocrine neoplasm (NEN) treated with peptide receptor radionuclide therapy (PRRT). SUBJECTS AND METHODS: Y-DOTA-TOC in 2 (6%) patients. No adverse effects of PRRT were recorded excerpt one patient who has died soon after the first therapy due to ileus after surgery. RESULTS: (Grade3). CONCLUSION: It can be concluded that PRRT according to a three-day nephroprotection protocol is a reliable and safe method of treatment for advanced NEN. Longer time to disease progression and overall survival in most patients underline the great potential of this treatment method in patients with advanced NEN.